Physician profile
Peter A Rienzi
NPI 1336177823
$5,676.50
in general payments reported to CMS, 2019-2025
43 companies · $1,561 in 2025
The $1,561 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $134 · 2021: $12.00 · 2022: $440 · 2023: $1,246 · 2024: $1,589 · 2025: $1,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,396.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $850.16 | 2021-2025 | |
| Novo Nordisk INC | $806.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $696.60 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $421.12 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $273.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Lundbeck LLC | $218.12 | 2024-2025 | Rexulti |
| Amgen INC. | $200.08 | 2019-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $199.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.69 | 2019-2025 | Jardiance, Spiriva Respimat |
| Janssen Pharmaceuticals, INC | $171.99 | 2019-2022 | |
| Astellas Pharma US INC | $170.88 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $170.34 | 2024-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $142.15 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $105.10 | 2019-2025 | Belsomra, Steglatro, Capvaxive |
| Sanofi-Aventis U.S. LLC | $94.21 | 2019-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $77.78 | 2023-2024 | |
| Renalytix Ai, INC. | $68.45 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Boston Scientific Corporation | $63.92 | 2024-2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $62.59 | 2022-2024 | |
| Seqirus USA INC | $56.96 | 2022-2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Vertical Pharmaceuticals, LLC | $49.03 | 2019 | |
| Insulet Corporation | $44.10 | 2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $41.90 | 2022-2023 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $40.80 | 2025 | Voquezna |
| Dexcom, INC. | $37.97 | 2023-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $35.64 | 2025 | Korlym |
| Sanofi Pasteur INC. | $35.55 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $35.02 | 2022-2025 | Eliquis |
| Esperion Therapeutics, INC. | $31.47 | 2024-2025 | Nexletol |
| Mannkind Corporation | $29.28 | 2019 | |
| Rgh Enterprises LLC | $26.93 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.74 | 2023 | Cuvitru |
| Otsuka America Pharmaceutical, INC. | $22.90 | 2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $22.84 | 2023 | Quviviq |
| Verona Pharma, INC. | $21.60 | 2025 | Ohtuvayre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.13 | 2025 | Xifaxan |
| Edwards Lifesciences Corporation | $19.85 | 2019 | |
| Sunovion Pharmaceuticals INC. | $18.82 | 2022 | |
| Tolmar, INC. | $17.90 | 2025 | Jatenzo |
| Ibsa Pharma INC. | $16.34 | 2025 | Licart, Flector, Tirosint |
| Dynavax Technologies Corporation | $15.86 | 2024 | Heplisav-B |
| Gilead Sciences, INC. | $15.06 | 2019 | |
| Sumitomo Pharma America, INC. | $14.17 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Rienzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.